FDA Approves Drug for Hypercortisolemia in Cushing’s Syndrome
December 30, 2021Descovy Granted Expanded Pediatric Indication for HIV
January 7, 2022January 4, 2022 – Par Pharmaceutical has launched the first generic version of Merz Pharmaceuticals’ Cuvposa® (glycopyrrolate) oral solution. Both Cuvposa and its generic are indicated to reduce chronic severe drooling in patients who are 3-16 years old and diagnosed with neurologic conditions (such as cerebral palsy) associated with problem drooling.
- Recommended initial dosing is 0.02mg/kg of the patient’s weight three times daily (taken by mouth), followed by titration of the dosage in 0.02mg/kg increments every 5-7 days, based on therapeutic response and adverse reactions. The maximum recommended dose is 0.1mg/kg three times daily, not to exceed a range of 1.5mg to 3mg per dose based on the patient’s weight. The medication should be administered at least one hour before or two hours after meals.
- The generic has a wholesale acquisition cost (WAC) of $399.60 per 473mL bottle, while the brand name has a WAC of $499.50 per bottle.